Posts

Lilly Highlights Low-Dose Zepbound and Foundayo for Long-Term Weight Loss Maintenance

on
Eli Lilly announced results from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN trials on May 12, 2026, showing effective weight loss maintenance. In SURMOUNT-MAINTAIN, participants on Zepbound maximum tolerated dose (MTD) maintained all prior weight loss; those reduced to 5 mg Zepbound maintained all but 5.6 kg after 52 weeks. In ATTAIN-MAINTAIN, switchers from Wegovy MTD to Foundayo maintained all but 0.9 kg; from Zepbound MTD to Foundayo maintained all but 5.0 kg after 52 weeks. Trials presented at 33rd European Congress on Obesity and published in The Lancet and Nature Medicine. Foundayo is a once-daily oral GLP-1; Zepbound maintenance doses include 5 mg, 10 mg, or 15 mg. Sources:

Takeda Restructuring: Over 600 US Layoffs Amid $1.3B Transformation Plan

on

Merck KGaA Axes SpringWorks Pipeline Assets Amid Pipeline Clear-Out While Pursuing M&A for External Innovation

on

BridgeBio's Attruby Challenges Pfizer's Tafamidis in ATTR-CM with Late-Stage Data Hinting at Superior Survival and Reduced Hospitalizations

on

Alkermes Advances Alixorexton to Phase 3 for Narcolepsy with Strong Mid-Stage Data

on

Rigel Pharmaceuticals Secures Licensing Deal for Arvinas and Pfizer's FDA-Approved Breast Cancer Drug VEPPANU

on

Five Burning Questions for Isomorphic Labs After $2.1B Raise

on

INNOVOTEX Appoints Jonathan Arambula to Executive Chairman

on

Faron to Present New BEXMAB Translational and Clinical Data in HR-MDS at EHA 2026

on

Quest Analytics Appoints Chris Lance as Chief Product Officer to Drive AI Innovation

on

Biotech's IPO Tide Turning Amid M&A Surge

on

Viewpoints: How iRhythm Technologies is Patching into the Future of Arrhythmia Detection

on

Roche Secures Second CE Mark for Eli Lilly-Co-Developed Alzheimer's Blood Test pTau217 in Europe

on